There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
Zhang Xiaodong
Beijing, Beijing Municipality, China
RECRUITINGoverall survival
Time frame: 2 year
adverse events
Time frame: after each cycle of chemotherapy
progression-free survival
Time frame: 1year
response rate
Time frame: every 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.